Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis
Abstract
Patient-reported quality-of-life (QoL) and carer impacts are not reported after leucine-rich glioma-inactivated 1-antibody encephalitis (LGI1-Ab-E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five-item battery explained most variance in QoL. Wide-ranging impacts post-LGI1-Ab-E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.
Citations
Altmetric:
Date
2024-02-01
Type
Article
Subject
Neurology
Collections
Citation
Binks SNM, Veldsman M, Handel AE, Jacob S, Maddison P, Coebergh J, Michael S, Ramanathan S, Easton A, Nissen MS, Leite MI, Okai D, Blaabjerg M, Husain M, Irani SR. Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis. Ann Clin Transl Neurol. 2024 Apr;11(4):1053-1058. doi: 10.1002/acn3.52006. Epub 2024 Feb 1.
Journal / Source Title
Annals of Clinical and Translational Neurology
DOI
10.1002/acn3.52006
PMID
38303486
Publisher
Wiley
Publisher’s URL
https://onlinelibrary.wiley.com/journal/23289503